PHILADELPHIA, May 7, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2012. The net loss for the period (including non-cash effects) was $2,308,000 or $(0.02) per share as compared to a net loss of $866,000 or ($0.01) per share for the same period in 2011. This year-to-year increase in net loss for the three month period of $1,442,000 (167%) was predominantly impacted by:
